TradingMenu expanded
Forge Markets Browse Companies
DataMenu expanded
Forge Data Private Market Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Freenome Stock

Freenome Stock

freenome.comHealthcare / BioTech & PharmaFounded: 2014Funding to Date: $1.1B

Freenome is a biotechnology company driven to provide the tools needed to detect, treat and prevent cancer using routing blood draw. This company was founded in 2014 by Gabe Otte, Riley Ennis, Charles Roberts and is headquartered in South San Francisco, CA. Freenome combines molecular biology with advanced computational biology and machine learning to help with early cancer detection.

Buy or sell Freenome stockLearn more about Freenome IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Freenome, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Freenome’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Freenome.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Freenome investors also invested in these private companies

Fidelity Investments
Andreessen Horowitz
GV
Polaris Partners
Perceptive Advisors
Kaiser Permanente Ventures

Team

Management Team

Charles Roberts
Co-Founder & Chief Growth Officer
Mike Nolan
Chief Executive Officer
Riley Ennis
Chief Product Officer
Jimmy Lin
Chief Scientific Officer
Julie Tran
Chief People Officer
Lance Baldo
Chief Medical Officer
Michael Ash
Chief Commercial Officer
Charles Roberts
Chief Growth Officer

Board Members

Douglas Robertson, MD
White River Junction Veterans Affairs Medical Center
Daniel F Hayes, MD
University of Michigan
William Grady, MD
Fred Hutchinson Cancer Research Center
Alberto Gutierrez, PhD
NDA Partners
Sherie Smalley, MD
AlohaCare

Frequently Asked Questions About Freenome’s Stock

plusminus
Can you buy Freenome stock?
Freenome is not publicly traded on NYSE or NASDAQ in the U.S. To buy Freenome stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Freenome stock?
Yes, you can sell stock of a private company like Freenome. Forge can help you sell your Freenome stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Freenome’s stock price?
Freenome is a privately held company and therefore does not have a public stock price. However, you may access Freenome’s private market stock price with Forge Data.
plusminus
What is Freenome’s stock ticker symbol?
Freenome does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like Freenome in the BioTech & Pharma sector

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$3.67B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

AI Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM

Atomwise

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$405.17MM

Mammoth Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.08B

Biosplice Therapeutics

Sector
Healthcare / BioTech & Pharma
 
 

Ginkgo Bioworks

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$4.89B

Caris Life Sciences

Sector
Healthcare / BioTech & Pharma
 
 

News Highlights

Walgreens Newsroom 06/15/2023
Walgreens and Freenome Partner to Increase Diversity in Research Focused on the Early Detection of Cancer
Walgreens and biotech firm Freenome have announced a multi-year partnership to advance clinical studies of Freenome's blood-based tests for early cancer detection. Walgreens will use its national footprint and patient insights to engage diverse patient populations in Freenome's multi-cancer research program. The partnership will also work on building risk-prediction models and population health software to help identify people eligible for standard-of-care cancer detection testing.
outsourcing-pharma.com 04/13/2023
University becomes Freenome's study partner for multi-cancer screening approach
The Institute for Population and Precision Health (IPPH) at the University of Chicago has partnered with biotech company Freenome for a study aimed at refining Freenome's multiomics platform for multi-cancer screening. The study, named Vallania, will use machine learning to detect cancer at early stages using a standard blood draw. This partnership is a significant step in Freenome's plan to expand early cancer detection beyond colorectal cancer.
BioSpace 03/28/2023
Freenome Adds Renown Health as Partner for the Sanderson Study
Freenome, a biotech company, has partnered with Renown Health for the Sanderson Study, which uses real-world data and multiomics for the detection of multiple cancers. The study aims to generate evidence of clinical validation for certain high-risk populations and refine the platform's cancer classification and risk prediction models. The Sanderson Study will enroll approximately 8,000 patients across the US.

Trending Companies

Frequently Asked Questions

Updated on: Dec 2, 2023

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.